The deeper current beneath both of these clocks is not really about MDMA or ibogaine separately. It is about which proof structure the American political and regulatory system will accept first — and what that acceptance then licenses. The FDA pathway demands double-blind rigor in a treatment context where blinding is structurally compromised by the phenomenology of the drug itself; that is not a solvable problem in the near term, and the agency knows it. The legislative pathway, by contrast, runs on a different evidentiary grammar: personal testimony, military service, bipartisan consensus, and a constituency — veterans — that both parties have learned they cannot afford to abandon. What is forming beneath the surface is a bifurcation of legitimacy: one treatment modality gaining institutional credibility through the body that most Americans trust least right now (the FDA, post-Lykos), and another gaining it through the body that still commands cross-partisan respect (the Armed Forces and the veterans who served in them). The highest trajectory available from here is not a race between these two pathways but a synthesis — where ibogaine's legislative momentum creates political pressure that reframes how the FDA thinks about novel proof structures for consciousness-altering therapies across the board.
For the veterans inside this story — the ones who flew to Mexico, who sat with ibogaine in clinics outside the legal system's protection, who came home changed and then had to explain that change to a VA system that had no category for it — today's signals carry something specific: the institutional world is beginning to build the vocabulary they have been living in for years. A Senate committee hearing, an NDAA vehicle attachment, a Stanford dataset entering the congressional record — these are not abstractions. They are the difference between a treatment that exists in the shadows and one that a veteran can ask for by name, covered, supervised, and safe. What becomes possible, if the current holds, is that the most underserved population in the mental health crisis becomes the population that opens the door for everyone else.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
This is not prediction. This is recognition.
74%
FDA rejects MDMA therapy, demands another trial on blinding
The FDA (the US drug regulator) will send back Lykos's MDMA-assisted therapy application with a Complete Response Letter — a formal rejection. The FDA will specifically cite two problems: the study wasn't properly blinded (meaning patients and therapists might have known who got real MDMA vs. placebo), and they don't have enough data on whether therapists followed the protocol consistently. This matters because it delays MDMA therapy by 3-5 years and signals the FDA is tightening its standards after the messy Lykos approval fight last year.
→ The FDA will reject MDMA therapy because the study wasn't rigorously blinded and therapist consistency wasn't proven well enough.
Resolves: 2026-09-30 · USA
REGULATORY
the precise call ▾
FDA issues a Complete Response Letter for MDMA-assisted therapy, citing inadequate blinding controls and therapist fidelity data, requiring at least one additional trial before resubmission.. The FDA's post-Lykos credibility repair mode, combined with a published reassessment paper validating internal agency skepticism about blinding integrity, makes approval without cleaner data politically and scientifically untenable. Precedent from the 2024 AdCom rejection and ongoing REMS scrutiny r
72%
Stanford's ibogaine study releases veteran outcomes by mid-2026
Stanford University, funded by the US Department of Defense (DOD), is running a trial of ibogaine for military veterans with PTSD and substance use disorder. By Q3 2026 (summer/fall), they will publish early results showing whether ibogaine actually helps these veterans. This matters because veterans' groups and their congressional allies are waiting for this data to push for policy change — ibogaine is currently illegal in the US.
→ Stanford will publish government-funded proof of whether ibogaine works for traumatized veterans, forcing a national conversation.
Resolves: 2026-09-30 · USA
RESEARCH
the precise call ▾
Stanford's DOD-funded ibogaine veteran trial will publicly release preliminary outcomes data by Q3 2026, directly cited in at least one congressional hearing or formal Senate briefing.. Stanford's program has active DOD funding and strong veteran advocacy pressure creating a predictable data-release-to-Capitol-Hill pipeline. Preliminary data release at this trial stage is standard, and congressional allies have publicly signaled they are waiting for this hook to stage hearings. Res
65%
Study published: MDMA blinding doesn't work in most trials
Scientists will publish a formal research review in a major journal (impact factor above 5 — meaning it's in the top tier of prestigious publications) that examines all the MDMA-assisted therapy trials and measures exactly how badly the blinding failed. Blinding failure means patients could tell whether they got real MDMA or placebo, which inflates how good the drug looks. This study will quantify the problem across multiple trials and show it's systematic, not a one-off mistake.
→ A major scientific publication will prove that most MDMA therapy trials had broken blinding, undermining claims that the drug works better than placebo.
Resolves: 2027-03-31 · Global
RESEARCH
the precise call ▾
A peer-reviewed meta-analysis formally quantifying blinding failure rates across MDMA-AT randomized controlled trials will be published in a journal with impact factor >5 by Q1 2027.. The blinding integrity problem is now the central scientific controversy in the field, with multiple groups independently collecting data. A meta-analysis is the natural methodological culmination and would be highly damaging to approval narratives. Specific falsifiability criteria: peer-reviewed, i
68%
A veteran testifies to Congress about their ibogaine treatment
A named veteran will go to Capitol Hill — either in person or via recorded video testimony — and tell members of Congress that ibogaine treated their PTSD, substance use, or both. Congress will hold a formal hearing or briefing. This will be the biggest psychedelic moment in politics that year because veteran testimony is extremely powerful in Congress, and it will come right after Stanford releases their data (see above), giving the story scientific weight.
→ A veteran will publicly tell Congress that ibogaine saved their life, turning a fringe drug into a national policy question.
Resolves: 2026-08-31 · USA
CULTURE
the precise call ▾
A named veteran will deliver live or recorded congressional testimony specifically about personal ibogaine treatment outcomes before September 2026, constituting the highest-profile psychedelic policy moment of the year.. Veteran testimony is the psychedelic reform coalition's most deployable political asset, and Stanford data release (see above) gives advocates the scientific cover needed to schedule a hearing. 'Highest-profile' is resolvable by media coverage metrics and C-SPAN viewership data vs. prior psychedelic
62%
Major news outlet exposes Republican ties to psychedelic companies
A top-tier US news outlet — think New York Times, Washington Post, Wall Street Journal, or The Atlantic — will publish an investigative piece about named Republican politicians or operatives who have financial stakes in psychedelic startups. The piece will document conflicts of interest: these politicians push psychedelic policy or funding while their allies or allies' companies stand to profit. This matters because it exposes how money shapes drug policy and could derail the Republican push to legalize psychedelics.
→ A major newspaper will expose that named Republican politicians have money in psychedelic companies while pushing policies that benefit those companies.
Resolves: 2026-09-01 · USA
CULTURE
the precise call ▾
A major investigative piece exposing financial conflicts of interest between named Republican political figures and venture-backed psychedelic companies will be published by a top-10 U.S. outlet before September 2026.. Two independent editorial signals — repeated coverage of the 'Republican Psychedelics Whisperer' and billionaire performance-drug framing — suggest an investigative piece is already in progress. The specific falsifiability criteria: named Republican, named company, top-10 outlet (NYT, WaPo, WSJ, Atl